Denali Therapeutics Inc.

NASDAQ: DNLI · Real-Time Price · USD
14.70
0.48 (3.38%)
At close: Jun 06, 2025, 3:59 PM
14.46
-1.63%
After-hours: Jun 06, 2025, 05:18 PM EDT

Denali Therapeutics Statistics

Share Statistics

Denali Therapeutics has 145.28M shares outstanding. The number of shares has increased by 1.83% in one year.

145.28M
1.83%
0.9%
75.51%
n/a
2,261
0.15%

Short Selling Information

The latest short interest is 12.1M, so 8.33% of the outstanding shares have been sold short.

12.1M
8.33%
9.33%
9.15

Valuation Ratios

The PE ratio is -7.93 and the forward PE ratio is -5.27. Denali Therapeutics's PEG ratio is -0.06.

-7.93
-5.27
0
2.9
2.73
-9.22
-0.06
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Denali Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 8.46, with a Debt / Equity ratio of 0.04.

8.46
8.46
0.04
-0.12
-0.13
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-954,340.86
443
0
n/a

Taxes

68K
-0.02%

Stock Price Statistics

The stock price has increased by -33.32% in the last 52 weeks. The beta is 1.33, so Denali Therapeutics's price volatility has been higher than the market average.

1.33
-33.32%
13.96
21.22
51.4
1,481,968

Income Statement

n/a
n/a
-487.34M
-422.77M
-414.91M
-422.7M
-2.57
Full Income Statement

Balance Sheet

The company has 174.96M in cash and 48.71M in debt, giving a net cash position of 126.25M.

174.96M
48.71M
126.25M
-1.54B
1.27B
786.76M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -347.69M and capital expenditures -15.91M, giving a free cash flow of -363.61M.

-347.69M
-15.91M
-363.61M
-2.21
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

DNLI does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for DNLI is $32.5, which is 128.7% higher than the current price. The consensus rating is "Buy".

$32.5
128.7%
Buy
16
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

5.21
2